Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Dose-Response Relationship, Drug And NotCristina Sampaio

List of bibliographic references

Number of relevant bibliographic references: 32.
Ident.Authors (with country if any)Title
000043 Wai Kin D. Ko [France] ; Elsa Pioli ; Qin Li ; Steve Mcguire ; Audrey Dufour ; Todd B. Sherer ; Erwan Bezard ; Maurizio F. FacherisCombined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
000087 Fabrizio Stocchi [Italie] ; Olivier Rascol ; Alain Destée [France] ; Nobutaka Hattori ; Robert A. Hauser ; Anthony E. Lang ; Werner Poewe [Autriche] ; Mark Stacy ; Eduardo Tolosa ; Haitao Gao ; Jennifer Nagel ; Martin Merschhemke ; Ana Graf ; Christopher Kenney ; Claudia TrenkwalderAFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
000098 Bruno Dubois [France] ; Eduardo Tolosa ; Regina Katzenschlager ; Murat Emre ; Andrew J. Lees ; Günther Schumann ; Emmanuelle Pourcher ; Julian Gray ; Gail Thomas ; Jina Swartz ; Timothy Hsu ; Margaret L. MolineDonepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study.
000206 Olivier Rascol [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] ; Anne-Marie Bonnet [France] ; Christine Brefel-Courbon [France] ; Pierre Césaro [France] ; Philippe Damier [France] ; Bérengère Debilly [France] ; Frank Durif [France] ; Monique Galitzky [France] ; Jean-Marie Grouin [France] ; Sylvie Pennaforte [France] ; Gabriel Villafane [France] ; Sadek Yaici [France] ; Yves Agid [France]Orodispersible sublingual piribedil to abort OFF episodes: A single dose placebo‐controlled, randomized, double‐blind, cross‐over study
000217 Olivier Rascol [France] ; Paolo Barone [Italie] ; Robert A. Hauser [États-Unis] ; Yoshikuni Mizuno [Japon] ; Werner Poewe [Autriche] ; Anthony H. V. Schapira [Royaume-Uni] ; Laurence Salin [France] ; Mandy Sohr [Allemagne] ; Catherine Debieuvre [France]Efficacy, safety, and tolerability of overnight switching from immediate‐ to once daily extended‐release pramipexole in early Parkinson's disease
000267 Donald Grosset [Royaume-Uni] ; Angelo Antonini [Italie] ; Margherita Canesi [Italie] ; Gianni Pezzoli [Italie] ; Andrew Lees (neurologue) [Royaume-Uni] ; Karen Shaw [Royaume-Uni] ; Esther Cubo [Espagne] ; Pablo Martinez-Martin [Espagne] ; Olivier Rascol [France] ; Laurence Negre-Pages [France] ; Ana Senard [France] ; Johannes Schwarz [Allemagne] ; Karl Strecker [Allemagne] ; Heinz Reichmann [Allemagne] ; Alexander Storch [Allemagne] ; Matthias Löhle [Allemagne] ; Fabrizio Stocchi [Italie] ; Katherine Grosset [Royaume-Uni]Adherence to antiparkinson medication in a multicenter European study
000308 C. Warren Olanow [États-Unis] ; Robert A. Hauser [États-Unis] ; Joseph Jankovic [États-Unis] ; William Langston [États-Unis] ; Anthony Lang [Canada] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Fabrizio Stocchi [Italie] ; Eldad Melamed [Israël] ; Eli Eyal [Israël] ; Olivier Rascol [France]A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics
000312 Adeline Gallini [France] ; Agnès Sommet [France] ; Anne-Marie Salandini [France] ; Patrick Veyssière [France] ; Jean-Louis Montastruc [France] ; Jean-Louis Montastruc [France]Weight‐loss associated with anti‐dementia drugs in a patient with Parkinson's disease
000322 Robert A. Hauser [États-Unis] ; Laurence Salin [France] ; Nolwenn Juhel [France] ; Victor L. Konyago [États-Unis]Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease
000360 Emmanuel Roze [France] ; Marie Vidailhet [France] ; Nenad Blau [Suisse] ; Lisbeth Birk Moller [Danemark] ; Diane Doummar [France] ; Thierry Billette De Villemeur [France] ; Anne Roubergue [France]Long‐term follow‐up and adult outcome of 6‐pyruvoyl‐tetrahydropterin synthase deficiency
000369 Olivier Rascol [France] ; Bruno Dubois [France] ; Alexandre Castro Caldas [Portugal] ; Stephen Senn [Royaume-Uni] ; Susanna Del Signore [France] ; Andrew Lees (neurologue) [Royaume-Uni]Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study
000383 Michael P. Hill [Royaume-Uni] ; Paula Ravenscroft [Royaume-Uni] ; Steven G. Mcguire [Royaume-Uni] ; Jonathan M. Brotchie [Royaume-Uni, Canada] ; Alan R. Crossman [Royaume-Uni] ; Catherine Rochat [France] ; Mark J. Millan [France]Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP‐lesioned marmosets: Mediation by D2, not D3, dopamine receptors
000406 Nicolas Simon [France] ; Joëlle Micallef [France] ; Jean-Charles Reynier [France] ; Monique Lesourd [France] ; Tatiana Witjas [France] ; André Alicherif [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France]End‐of‐dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: A pharmacokinetic/pharmacodynamic, randomized, double‐blind study
000455 Marc Ziegler ; Alexandre Castro-Caldas [Portugal] ; Susanna Del Signore [France] ; Olivier Rascol [France]Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6‐month, randomized, placebo‐controlled study
000510 Olivier Rascol [France] ; I. Arnulf [France] ; H. Peyro-Saint Paul [France] ; C. Brefel-Courbon [France] ; M. Vidailhet [France] ; C. Thalamas [France] ; A. M. Bonnet [France] ; S. Descombes [France] ; B. Bejjani [France] ; N. Fabre [France] ; J. L. Montastruc [France] ; Yves Agid [France]Idazoxan, an alpha‐2 antagonist, and L‐DOPA‐induced dyskinesias in patients with Parkinson's disease
000535 Jean Louis Montastruc [France] ; Olivier Rascol [France] ; Jean-Michel Senard [France]Treatment of Parkinson's disease should begin with a dopamine agonist
000545 Yves Agid [France] ; E. Ahlskog [France] ; A. Albanese [France] ; D. Calne [France] ; T. Chase [France] ; J. De Yebenes [France] ; S. Factor [France] ; S. Fahn [France] ; O. Gershanik [France] ; C. Goetz [France] ; W. Koller [France] ; M. Kurth [France] ; A. Lang [France] ; A. Lees [France] ; P. Lewitt [France] ; D. Marsden [France] ; E. Melamed [France] ; P. P. Michel [France] ; Y. Mizuno [France] ; J. Obeso [France] ; W. Oertel [France] ; W. Olanow [France] ; Werner Poewe [France] ; Pierre Pollak [France] ; S. Przedzorski [France] ; N. Quinn [France] ; R. Raisman-Vozari [France] ; A. Rajput [France] ; F. Stocchi [France] ; E. Tolosa [France]Levodopa in the treatment of Parkinson's disease: A consensus meeting viewpoint
000553 M. Vidailhet [France] ; A. M. Bonnet [France] ; R. Marconi [France] ; F. Durif [France] ; Yves Agid [France]The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease
000556 Olivier Rascol [France]L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease : A clinical pharmacologic approach
000557 P. Damier [France] ; C. Jaillon [France] ; I. Clavier [France] ; I. Arnulf [France] ; A.-M. Bonnet [France] ; B.-P. Bejjani [France] ; Yves Agid [France]Dyskinesias assessment in phase II studies
000558 H. Widner [Suède] ; G.-L. Defer [France]Dyskinesias assessment : From CAPIT to CAPSIT
000566 Paul Krack [Allemagne] ; Günther Deuschl [Allemagne] ; Reiner Benecke [Allemagne] ; Andres O. Ceballos-Baumann [Allemagne] ; Marie-Hélène Marion [France] ; Rue Léon Delhomme [France] ; Wolfgang H. Oertel [Allemagne] ; Werner Poewe [Autriche] ; K. Wohlfarth [Allemagne, France, Autriche, Italie, États-Unis] ; H. Göschel [Allemagne, France, Autriche, Italie, États-Unis] ; J. Frevert [Allemagne, France, Autriche, Italie, États-Unis] ; R. Dengler [Allemagne, France, Autriche, Italie, États-Unis] ; H. Bigalke [Allemagne, France, Autriche, Italie, États-Unis] ; Pasquale Montagna [Italie] ; Elio Lugaresi [Italie] ; Stanley Fahn [États-Unis] ; Virgilio Gerald H. Evidente [États-Unis] ; Katrina A. Gwinn [États-Unis]Letters to the Editor
000569 Rascol [France] ; Kasia Sieradzan [Royaume-Uni] ; Hélène Peyro-Saint-Paul [France] ; Claire Thalamas [France] ; Christine Brefel-Courbon [France] ; Jean Michel Senard [France] ; Philippe Ladure [France] ; Jean Louis Montastruc [France] ; Andrew Lees (neurologue) [Royaume-Uni]Efaroxan, an alpha‐2 antagonist, in the treatment of progressive supranuclear palsy
000591 Nathalie Andreu [France] ; Christine Damase-Michel [France] ; Jean-Michel Senard [France] ; Olivier Rascol [France] ; Montastruc [France]A dose‐ranging study of selegiline in patients with Parkinson's disease: Effect on platelet monoamine oxidase activity
000617 Limousin [France] ; Pierre Pollak [France] ; Abdelhamid Benazzouz [France] ; Dominique Hoffmann [France] ; Emmanuel Broussolle [France] ; Jean Edmond Perret [France] ; Alim-Louis Benabid [France]Bilateral subthalamic nucleus stimulation for severe Parkinson's disease
000627 P. Krack [Allemagne] ; Marion [France]“Apraxia of lid opening,” a focal eyelid dystonia: Clinical study of 32 patients
000628 J. L. Montastruc [France] ; N. Fabre [France] ; Olivier Rascol [France] ; J. M. Senard [France] ; O. Blin [France]N‐methyl‐D‐aspartate (NMDA) antagonist and Parkinson's disease: A pilot study with dextromethorphan
000629 Rascol [France] ; Nelly Fabre [France] ; Olivier Blin [France] ; Janet Poulik [France] ; Umberto Sabatini [France] ; Jean-Michel Senard [France] ; Michèle Ané [France] ; Jean-Louis Montastruc [France] ; André Rascol [France]Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease
000630 Roberto Marconi [France, Italie] ; Dominique Lefebvre-Caparros [France] ; Anne-Marie Bonnet [France] ; Marie Vidailhet [France] ; Bruno Dubois [France] ; Agid [France]Levodopa‐induced dyskinesias in Parkinson's disease phenomenology and pathophysiology
000644 M. Vidailhet [France] ; C. Bouchard [France] ; P. J. Jedynak [France] ; M. Serdaru [France]Acute and long‐term response to apomorphine in cranial dystonia
000653 Rektor [Tchécoslovaquie] ; Milada Švejdová [France] ; Carmen Silva-Barrat [Tchécoslovaquie] ; Christian Menini [France]Influence of cholinergic system on myoclonus in myoclonic epilepsies
000654 Emre [Suisse] ; U. K. Rinne [Finlande] ; A. Rascol [France] ; A. Lees [Royaume-Uni] ; Yves Agid [France] ; X. Lataste [Suisse]Effects of a selective partil D1 agonist, CY 208‐243, in de novo patients with Parkinson disease

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024